Cargando…
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
Vertical growth phase (VGP) melanoma is frequently metastatic, a process mediated by changes in gene expression, which are directed by signal transduction pathways in the tumor cells. A prominent signaling pathway is the Ras-Raf-Mek-Erk MAPK pathway, which increases expression of genes that promote...
Autores principales: | Jenkins, Molly H., Croteau, Walburga, Mullins, David W., Brinckerhoff, Constance E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048745/ https://www.ncbi.nlm.nih.gov/pubmed/25989506 http://dx.doi.org/10.1016/j.matbio.2015.05.007 |
Ejemplares similares
-
Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010) -
Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021) -
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010) -
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010) -
Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment
por: Erdmann, Sarah, et al.
Publicado: (2019)